The Therapeutics Development segment is the core of Avidity Biosciences' operations, focusing on the research, development, and clinical evaluation of Antibody Oligonucleotide Conjugates (AOCs). This segment encompasses the entire drug development lifecycle, from early-stage discovery and preclinical studies to clinical trials and regulatory submissions. Key technologies include the proprietary AOC platform, which combines the precision of oligonucleotide therapeutics with the targeting capabilities of antibodies. The segment is primarily focused on rare neuromuscular diseases, including myotonic dystrophy type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Patient impact is addressed through the potential for disease-modifying therapies that address the underlying causes of these conditions. Market positioning is driven by the innovative AOC technology, offering a competitive advantage in the field of RNA therapeutics. Future opportunities include expanding the AOC platform to other therapeutic areas and advancing clinical programs. Regulatory and clinical aspects involve navigating FDA and other regulatory bodies for approvals. Partnerships and collaborations with companies like Bristol Myers Squibb and Eli Lilly support research and development efforts.